Literature DB >> 28620001

Inhibition of Pancreatic Cancer by RhIL1RA-Response.

Paul J Chiao1, Jianhua Ling2, Jie Fu2, Yu Lu3, Yi-Chen Sun4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28620001      PMCID： PMC5909702          DOI： 10.1158/1078-0432.CCR-17-0083

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  4 in total

1.  Coix seed emulsion synergistically enhances the antitumor activity of gemcitabine in pancreatic cancer through abrogation of NF-κB signaling.

Authors:  Yafang Qian; Bo Yang; Yang Xiong; Mancang Gu
Journal:  Oncol Rep       Date:  2016-07-21       Impact factor: 3.906

2.  New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.

Authors:  Takashi Horiuchi; Tadashi Uwagawa; Yoshihiro Shirai; Nobuhiro Saito; Ryota Iwase; Koichiro Haruki; Hiroaki Shiba; Toya Ohashi; Katsuhiko Yanaga
Journal:  J Surg Res       Date:  2016-06-25       Impact factor: 2.192

3.  Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade.

Authors:  Zhengle Zhang; Qingke Duan; Hengqiang Zhao; Tao Liu; Heshui Wu; Qiang Shen; Chunyou Wang; Tao Yin
Journal:  Cancer Lett       Date:  2016-08-26       Impact factor: 8.679

4.  IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation.

Authors:  Zhuonan Zhuang; Huai-Qiang Ju; Mitzi Aguilar; Takashi Gocho; Hao Li; Tomonori Iida; Harold Lee; Xiaoqiang Fan; Haijun Zhou; Jianhua Ling; Zhongkui Li; Jie Fu; Min Wu; Min Li; Davide Melisi; Yoichiro Iwakura; Kesen Xu; Jason B Fleming; Paul J Chiao
Journal:  Clin Cancer Res       Date:  2015-10-23       Impact factor: 12.531
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.